<DOC>
	<DOCNO>NCT00287768</DOCNO>
	<brief_summary>The primary objective study compare median overall survival test arm ( docetaxel S-1 ) control arm ( S-1 ) subject advanced recurrent gastric cancer .</brief_summary>
	<brief_title>Phase III Study Docetaxel + S-1 vs. S-1 Advanced Gastric Cancer</brief_title>
	<detailed_description>Seven-hundred fifty thousand new gastric cancer case diagnose worldwide per year . Advanced gastric cancer ( AGC ) consider nearly incurable less 10 % subject alive 5 year diagnosis . Therefore , new treatment regimen need subject AGC . S-1 , new oral fluoropyrimidine consist 5-FU prodrug tegafur ( ftorafur , FT ) two enzyme inhibitor , CDHP ( 5-chloro-2,4-dihydroxypyridine ) OXO ( potassium oxonate ) , molar ratio 1 ( FT ) :0.4 ( CDHP ) :1 ( OXO ) commercially available since late 90'in Japan . Phase II trial demonstrate S-1 active , single agent , treatment gastric ( RR 44.6 % ) , colorectal ( RR 37.4 % ) , head neck , breast , non-small cell lung , pancreatic cancer . In gastric cancer , phase III trial ( JCOG 9912 ) compare 5-FU alone CPT-11/CDDP combination currently underway result await . Despite JCOG 9912 study ongoing , 80 % patient AGC already treat S-1 , high RR convenience use out-patient basis . P-II study S-1/CDDP , S-1/CPT-11 S-1/Docetaxel show high RR ( 55-76 % ) long MST ( 12-14M ) . Furthermore , P-III study already conduct S-1 vs. S-1/CDDP S-1 vs. S-1/CPT-11 Japan . The aim study compare S-1/Docetaxel vs. S-1 alone patient AGC . This study prospective , multicenter , multinational , non-blinded , randomized phase III study . Patients : Inoperable relapse gastric cancer . Informed consent must obtain write treatment . Subjects meet inclusion criterion exclusion criterion consider enrollment study . Then patient randomly assign two group S-1/Docetaxel ( Treatment Arm A ) S-1 alone ( Treatment Arm B ) .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically proven operable advanced gastric adenocarcinoma ( include adenocarcinoma gastrooesophageal junction ) relapse gastric adenocarcinoma Subjects must able take orally Measurable lesion and/or nonmeasurable lesion define RECIST ECOG performance status ≦ 1 Hgb ≧ 8g/dL , WBC 400012000/mm3 , platelet ≧ 100,000/mm3 Creatine ≦ upper normal limit ( UNL ) Total bilirubin ≦ 1.5 X UNL AST , ALT ALP ≦ 2.5 x UNL No prior chemotherapy Life expectancy estimate 3 month Written inform consent Active double cancer Gastrointestinal bleeding Excessive amount ascites require drainage Known brain metastasis Symptomatic peripheral neuropathy ≧ garde 2. NCICTCAE ver.3.0 Pulmonary fibrosis , Intestinal pneumonitis History hypersensitivity fluoropyrimidines , docetaxel medication formulate polysorbate 80 Any previous chemotherapy radiotherapy AGC Pregnancy lactation woman , woman suspect pregnancy men willing get pregnant Treatment investigational product last 4 week prior study entry Definite contraindication use corticosteroid Any subject judge investigator unfit reason participate study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>advanced gastric cancer</keyword>
	<keyword>S-1</keyword>
	<keyword>docetaxel</keyword>
	<keyword>phase III study</keyword>
</DOC>